Applications, hearings, determinations, etc.: Noramco, Inc.,

[Federal Register: April 5, 2005 (Volume 70, Number 64)]

[Notices]

[Page 17262]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr05ap05-61]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By notice dated December 21, 2004, and published in the Federal Register on January 4, 2005 (70 FR 392-393), Noramco Inc., Division of Ortho-McNeil, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal and by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Dihydrocodeine (9120), a basic class of controlled substance listed in Schedule II.

The company plans to manufacture the listed controlled substance in bulk for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: March 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 05-6695 Filed 4-4-05; 8:45 am]

BILLING CODE 4410-09-P

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT